improving health through evidence-based probiotics€¦ · ecologic® barrier reduced risk taking...
TRANSCRIPT
wincloveprobiotics.com
Improving health through evidence-based probiotics
Company Profile & Probiotic Portfolio
vw
Company Profile
Winclove Probiotics, established in Amsterdam, The Netherlands, has been specializing in research, development and manufacturing of probiotic formulations for over 25 years.
Our probiotic formulations are developed in close collaboration with leading research institutes, universities and academic hospitals. This enables us to develop innovative multispecies probiotic formulations for many different health indications.
We continuously invest in research and technologies in order to develop the most effective probiotics that ensure end-users with the best solution.
Winclove Probiotics
Developing probiotic formulations since 1991 with a strong emphasis on research
Looking for business opportunities?
Winclove’s mission is to create long-lasting, sustainable and strategic partnerships. To achieve this, we offer innovative, high-quality and competitive probiotic solutions, as well as in-house scientific expertise and sales support.
Our indication-specific formulations are designed for specific microbiota-related indications. The thorough substantiation of our probiotic formulations with scien-tific and clinical evidence makes them ideal for selling medically endorsed.
We are a committed business partner and are looking forward to starting a fruitful collaboration with you!
Product package
Development of the formulation
Research collaboration
Probiotic blend
Dossiers Technical lab analysis, in vitro data, etc.Clinical in vivo studies, post market studies, user trials
Training & education
• Training and education for salesforce & healthcare professionals
• Round tables with KOLs
• Sharing best practices other countries
• Monthly news update
• Independent scientific conferences
Sales & marketing support
QA & RA
Ecologic® formulationsOur Ecologic® formulations have been developed in collaboration with leading universities and academic hospitals worldwide. For every indication bacterial strains are selected based on characteristics and functionality, and the formulation has been proven effective in clinical trials.
Key strengths of our formulations• Indication-specific selection
of bacteria• Evidence-based formulations• Stability at room temperature,
no refrigeration needed• Excellent survival of the
gastro-intestinal tract• High viability and metabolically
active bacteria• Flexible packaging; from bulk
delivery to fully packed
Winclove formulationsWinclove formulations consist of carefully selected probiotic strains and are based on scientific and in vitro evidence.
Managing allergic symptoms; hay fever and eczema
Preventing early-onset eczema
Allergy
Reducing antibiotic-associated side effects
Reducing constipation
Reducing exercise-induced stress
Gut
Improving intestinal health in newborns
Improving intestinal health in children
Improving intestinal health in adults
Improving intestinal health of elderly
Age
Reducing vulnerability to depression
Improving brain functioning under stress
Brain
P R O B I O AC T ® T E C H N O LO G Y
Protective and nutritional ingredients, specifically selected and tested to increase:
• Shelf life of the formulation
• Gastro-intestinal survival of the bacteria
• Activity of the bacteria in the intestine
Probiotic portfolio
Reducing antibiotic-associated side effects
Reducing constipation
Reducing exercise-induced stress
Preventing traveler’s diarrhea
This information is for professionals only and should not be given to consumers
Over the last decades, driven by the fascination for bacteria, Winclove has built an extensive database of well characterized probiotic strains. This unique knowledge enables us to develop evidence-based multispecies probiotic formulations for a wide range of microbiota-related indications. In collaboration with research partners, these formulations are tested in clinical trials and published in peer-reviewed journals.
P I O N E E R I N P R O B I OT I C R E S E A R C H
Gut-brain
Allergy
Drug related effects
Ear, nose & throat
Gastrointestinal
Cardiometabolic
Urogenital
Research and development areas
The effect of Ecologic® BARRIER on vul-nerability for depression was tested in a triple-blind, placebo-controlled, rand-omized, human trial, performed by Leiden University, The Netherlands. The research-ers investigated the effect of Ecologic® BARRIER on cognitive reactivity to sad mood using the Leiden Index of depres-sion sensitivity scale (LEIDS-r). 40 healthy participants received 2 grams Ecologic® BARRIER or placebo for 4 weeks. The re-sults showed that Ecologic® BARRIER sig-nificantly reduced overall cognitive reac-tivity to sad mood2 (see figure 1).
Multiple, placebo-controlled, rat studies were performed with Ecologic® BARRI-ER by Aarhus University, Denmark, using wild type rats and a genetic rat model for depression.3-6 In the genetic model, Ecologic® BARRIER reduced risk taking be-havior and prevented the exacerbation of depressive-like behavior normally induced by a high-fat diet. In the wild-type rats, Ecologic® BARRIER significantly reduced depressive-like behavior, measured by a forced swim test (see figure 2), and dif-ferences in gut microbiota between re-sponder and non-responder animals were identified. Ecologic® BARRIER influenced gene-expression in the hippocampus and altered immunological and metabolic markers, explaining the positive outcomes.
Moreover, researchers from Radboud Uni-versity Nijmegen and Donders Intsitute for Brain Cognition and Behavior, The Nether-lands, performed a double-blind, placebo- controlled, random ized, human trial with Ecologic® BARRIER. The researchers investigated the effect on neurocog-nition, using functional magnetic res-onance imaging (fMRI), and stress-in-duced working memory performance meausured by a Digit Span Backwards test. 58 participants received 2 grams of Ecologic® BARRIER or placebo for 4 weeks. Ecologic® BARRIER significant-ly increased working memory perfor-mance7 (see figure 3). Ecologic® BARRIER buffered against the damaging effects of stress on brain functioning.
- Reducing vulnerability to depression - Improving brain functioning under stress
Figure 2: Seconds of immobility during the Forced Swim Test. *Significant decrease, p<0.001.
Imm
obilit
y (s
ec)
Placebo Ecologic® BARRIER
-0.2
-0.4
-0.6
-0.8
-1
0.8
0.6
0.4
0.2
0
50
100
150
200
250
0
5
50
10
15
20
25
30
35
40
45 * *
0
*
Figure 1: LEIDS-r scores before and after 4 weeks of supplementation with Ecologic® BARRIER. *Significant decrease, p<0.001.
LEID
S-r s
core
s
Baseline Intervention
-0.2
-0.4
-0.6
-0.8
-1
0.8
0.6
0.4
0.2
0
50
100
150
200
250
0
5
50
10
15
20
25
30
35
40
45 * *
0
*
Placebo Ecologic® BARRIER
Figure 3: Stress-induced changes in working memory. Calculated as the difference of DS backwards scores after stress minus scores before stress. *Significant differences, p<0.05.
DS
back
war
ds, a
fter-
befo
re s
tress
-0.2
-0.4
-0.6
-0.8
-1
0.8
0.6
0.4
0.2
0
50
100
150
200
250
0
5
50
10
15
20
25
30
35
40
45 * *
0
*
Placebo pre- test Placebo post- test
Probiotics pre- test Probiotics post- test
The bacterial strains in Ecologic® BARRIER have been selected for their capacity to strengthen the intestinal barrier function and reduce low grade inflammation1. The strains have been screened in vitro for their capacity to:• improve the intestinal barrier function• inhibit mast cell activation• stimulate IL-10 production• break down lipopolysaccharides (LPS).
Ecologic® BARRIER is a multispecies formulation consisting of 9 bac-terial strains, 2,5 x 109 CFU/gram. The recommended dosage is 2 grams a day.
• B. bifidum W23• B. lactis W51• B. lactis W52
1. van Hemert et al. Influence of the multispecies probiotic Ecologic® BARRIER on parame-ters of intestinal barrier function. Food and Nutrition Sciences 2014.
2. Steenbergen et al. A randomized controlled trial to test the effect of multispecies probi-otics on cognitive reactivity to sad mood. Brain Behav Immun 2015;48:258-64.
3. Abildgaard, et al. Probiotic treatment reduces depressive-like behaviour in rats inde-pendently of diet. Psychoneuroendocrin 2017;79:40-48.
4. Abildgaard, et al. Probiotic treatment protects against the pro-depressant-like effect of high-fat diet in Flinders Sensitive Line rats. Brain Behav Immunity 2017;65:33–42.
5. Tillmann, et al. Probiotics reduce risk-taking behavior in the Elevated Plus Maze in the Flinders Sensitive Line rat model of depression. Behav Brain Res 2019;359:755-762.
6. Abildgaard, et al. The antidepressant-like effect of probiotics and their faecal abundance may be modulated by the cohabiting gut microbiota in rats. Eur Neuropsychopharmacol 2019;29(1):98-110.
7. Papalini, et al. Stress matters: Randomized controlled trial on the effect of probiotics on neurocognition, Neurobiology of Stress 2019;10:100141
Strain selection Bacterial strains
Clinical evidence
References Ecologic® BARRIER publications
• L. acidophilus W37• L. brevis W63• L. casei W56
• L. salivarius W24 • Lc. lactis W19• Lc. lactis W58
The probiotic strains in Ecologic® ALLERGYCARE have been selected to influence the immune system. The strains have been screened in vitro for their capacity to:
• Modulate production of immuno suppressive cytokines by; - induction of IL-10 and IFN-y - reduction of IL-4, IL-5 and IL-13.
Ecologic® ALLERGYCARE is a multispecies formulation consisting of 6 probiotic strains, 1 x 109 CFU/gram. The recommended dosage is 2 grams, twice daily.
• B. bifidum W23• B. lactis W51 • L. acidophilus W55• L. casei W56
Managing allergic symptoms:hay fever and eczema
1. Yesilova Y, Calka O, et al. Effect of probiotics on the treatment of children with atopic dermatitis. Ann Dermatol 2012;24:189-93.
2. Watts AM, et al. Probiotics and Allergic Rhinitis: A Simon Two-Stage Design to Determine Effectiveness. J Altern Complement Med. 2016;22(12):1007-1012.
3. Watts AM, Cox AJ, et al. A Specifically Designed Multispecies Probiotic Supplement Relieves Seasonal Allergic Rhinitis Symptoms. Altern Complement Med. 2018;24(8):833-840.
Strain selection
Clinical evidence
References
The effect of Ecologic® ALLERGYCARE on atopic dermatitis (AD) symptoms has been tested in a double-blind, randomized, placebo-controlled human trial, performed by Harran University, Turkey1. Forty children between 1-13 years of age suffering from AD received 2x109 CFU Ecologic® ALLERGYCARE or pla-cebo twice dai ly for eight weeks. Both clinical and mechanis tic effects were measured at baseline and at the end of the intervention period. Ecologic® ALLERGYCARE significantly reduced the SCORing Atopic Dermatitis (SCO-
RAD) index. (see figure 1). These results are supported by the finding that total IgE levels were significantly dropped in the probiotic group, compared to the placebo group.
The effect of Ecologic® ALLERGYCARE on quality of life (QoL) in patients with allergic rhinitis (AR) has been tested in a clinical trial performed by Griffith Univer-sity Australia2,3. Forty hay fever patients received 2x109 CFU Ecologic® ALLERGY-CARE twice daily for eight weeks. Before and after the intervention period, QoL
was determined using the rhinitis qual-ity of life questionnaire (RQLQ). During the intervention patients also record-ed AR symptoms and medication use. Ecologic® ALLERGYCARE significantly improved QoL in 63% of the patients (meaningful improvement >0.7 decrease in the RQLQ, p=0.005). The average RQLQ score dropped from 2.83 at base-line to 1.66 at midpoint to 1.38 at week 8 (see figure 2). In line with these findings, a trend towards reduction in AR symptoms and medication use was found.
Figure 1: Changes in the SCORAD-index before and after the intervention. * Significant decrease, p=0.005.
Figure 2: RQLQ scores during the intervention. * Significant decrease, p=0.005.
0
5
50
*10
15
20
25
30
35
40
45
**
1
2
3
RQLQ
sco
re
Baseline 4 weeks supplementation
8 weeks supplementation
0
5
50
*10
15
20
25
30
35
40
45
**
1
2
3
SCO
RAD
%
Baseline 8 weeks supplementation
Placebo Ecologic® ALLERGYCARE
Ecologic® ALLERGYCARE publications
• L. salivarius W57• Lc. lactis W58vitamin B2 and biotin
Bacterial strains
The probiotic strains in Ecologic® PANDA have been selected for their capacity to strengthen the intestinal barrier function and influ-ence the immune system1,2. The strains have been screened in vitro for their capacity to:
• improve the intestinal barrier function• modulate the production of immuno suppressive cytokines.
Ecologic® PANDA is a multispecies formulation consisting of 4 probi-otic strains, 1 x 109 CFU/gram. The recommended dosage is 3 grams a day. The treatment period for pregnant women is 6-8 weeks before delivery and for babies the first year of life.
• B. bifidum W23• B. lactis W51
Preventing early onset eczema
1. Niers L.E. et al. Identification of strong interleukin-10 inducing lactic acid bacteria which down-regulate T helper type 2 cytokines. Clin Exp Allergy. 2005;35(11):1481-1489.
2. Niers L.E. et al. Selection of probiotic bacteria for prevention of allergic diseases: immunomodulation of neonatal dendritic cells. Clin Exp Immunol. 2007;149(2):344-352.
3. Niers L.E. et al. The effects of selected probiotic strains on the development of eczema (the PandA study). Allergy. 2009;64(9):1349-1358.
4. Niers L.E. Probiotic bacteria for prevention of atopic disease. Design and application. PhD thesis. November 2009.
5. Gorissen et al. Preventive effects of selected probiotic strains on the development of asthma and allergic rhinitis in childhood. The Panda study. Clin Exp Allergy. 2014;44(11):1431-3.
6. Rutten N.B.M.M. et al. Long Term Development of Gut Microbiota Composition in Atopic Children: Impact of Probiotics. PLoS ONE. 2015;10(9): e01376812015.
7. Kim H.K. et al. Probiotic supplementation influences faecal short chain fatty acids in infants at high risk for eczema. Benef Microbes. 2015; 6(6): 783-790.
8. Hofmann H. Probiotics for indigestion in pregnancy and infant colic. Gyneacology, 26-11-2015.
Strain selection
Clinical evidence
References
Ecologic® PANDA has been tested in a randomized, double-blinded, place-bo-controlled trial including 102 pregnant women who were at high risk of getting an allergic baby due to a positive family history (the PandA study). Subjects re-ceived either Ecologic® PANDA or a pla-cebo, which was administered prenatally (in the diet during pregnancy 6-8 weeks prior to delivery) and postnatally (during the first 12 months of life to the child). The results showed a significant reduc-tion of eczema after 3 months in the babies receiving Ecologic® PANDA, and a sustainment of this effect until two
years after birth3 (figure 1). Results sub-stantiated previous research outcomes by showing that babies who did not de-velop eczema had a higher microbial di-versity. All phases of the research that led to this formulation have been published in a PhD thesis4.
The children in the PandA trial were fol-lowed till the age of 5 years. No long-term effects were found,5 which is in line with similar other studies. The re-searchers did find higher quantities of Ecologic® PANDA strains in microbiota samples during the intervention period,
indicating good GI-survival of the bac-terial strains6. Also, a possible mecha-nism for the explanation of the positive outcomes of the PandA trial was found. Higher concentrations of SCFAs were found in faecal samples of the children who received Ecologic® PANDA com-pared to the placebo group7 (figure 2). The findings are in line with other stud-ies that have shown the potential role of SCFAs in eczema.
In an observational trial it has been found that Ecologic® PANDA also benefits chil-dren after birth by reducing colic8.
Figure 1: Ecologic® PANDA shows a significant reduction of eczema development.* Significant effect, p<0.05.
Figure 2: Faecal concentrations SCFAs by 3 months of age.
Ecologic® PANDA publications
Placebo Ecologic® PANDA Placebo Ecologic® PANDA
0
0,1
0,2
0,3
0,4
0,5
0,6
0,7
0,8
0
10
20
30
40
*
0
0,1
0,2
0,3
0,4
0,5
0,6
0,7
0,8
0
10
20
30
40
*
Acetate Propionate n-Butyrate Total SCFA3 12 24 Months
CU
MU
LATI
VE
INC
IDEN
CE
OF
ATO
PIC
EC
ZEM
A
• B. lactis W52 • Lc. lactis W58
Bacterial strains
1. Koning C.J.M et al. The Effect of a Multispecies Probiotic on the Intestinal Microbiota and Bowel Movements in Healthy Volunteers Taking the Antibiotic Amoxycillin. Am J Gastroenterol 2007;102:1–12.
2. Koning C.J.M. Multispecies probiotics and antibioticsassociated side effects. PhD Thesis. 2010.
3. Lang F.C. Use of a multi-species probiotics for the prevention of antibiotic associated diarrhea. Nutrafoods 2010;9(2); 27-31.
4. Hell M, et al. Probiotics in Clostridium difficile infection: reviewing the need for a multist-rain probiotic.Benef Microbes. 2013;4(1):39-51.
5. WAO Guidelines, Probiotics and Prebiotics Feb 2017.
Reducing antibiotic-associated side effects
Clinical evidence
References
Ecologic® AAD has been tested in a rand-omized, double-blind, placebo-controlled trial with healthy volunteers taking amox-icillin, performed by Maastricht University Medical Centre, The Netherlands1. The trial showed that Ecologic® AAD significantly reduced the risk of diarrhoea-like def-ecation (figure 1). It was also shown that the intestinal microbiota of participants in the probiotic group restored faster to the pre-antibiotic state than the intestinal microbiota of participants in the placebo group2. The results therefore suggest that restoration of the intestinal microbiota is
one of the important mechanisms deter-mining the efficacy of probiotics in AAD (figure 2). Ecologic® AAD was also able to stimulate the production of cytokine se-cretory IgA (sIgA), an important immuno-globulin for the general defence against pathogens. This result has been confirmed in a user trial in Austria with 199 participants. Hos-pitalised patients on antibiotics received Ecologic® AAD which resulted in a signifi-cantly lower incidence of AAD. Less than 1% in the entire study group developed AAD3, which normally ranges between
5-39%. Furthermore, in a retrospective case re-port series of 10 patients with C. difficile infection (CDI), of whom 5 experienced recurrent CDI, twice-daily supplementa-tion with Ecologic® AAD, besides antibiot-ics, resulted in complete recovery4.Ecologic® AAD is recommended by the World Gastroenterology Organisation in their Global Guidelines (feb 2017).5 The level of evidence on reducing antibiot-ic-associated diarrhoea is evaluated as level 2 evidence: Randomized trial or observational study with dramatic effect.
Ecologic® AAD publications
Figure 1: Diarrhea-like defecation occurred significantly less in the Ecologic® AAD group compared to the placebo group.
Figure 2: After day 35 there is a significantly faster recovery to the pre-antibiotic state of the microbiota in the Ecologic® AAD group compared to the placebo group.
Ecologic® AAD Placebo
0
10
20
30
40
50
60
70
80
90
100
0 3 7 14 35 63
Sim
ilarit
y (%
)
Diar
rhoe
a (%
)
90
80
70
60
50
40
30
20
10
0
48%
79%
*
Days
Ecologic® AAD Placebo
The probiotic strains in Ecologic® AAD have been selected for their capacity to inhibit antibiotic-associated diarrhoea (AAD)-related pathogens. The strains have been screened in vitro for their capacity to inhibit growth of the pathogens:
• Clostridium difficile• Clostridium perfringens• Entercoccus faecalis• Escheria coli • Bacillus subtilus.
Ecologic® AAD is a multispecies formulation consisting of 9 probiot-ic strains, 1 x 109 CFU/gram. The recommended dosage is 5 grams, twice daily. It is adviced to start supplementation from the first day of antibiotic treatment until one week after cessation.
• B. bifidum W23• B. lactis W51• E. faecium W54• L. acidophilus W37• L. acidophilus W55
Strain selection
• L. paracasei W20• L. plantarum W62• L. rhamnosus W71• L. salivarius W24
Bacterial strains
1. Bekkali N. et al. The role of a probiotics mixture in the treatment of child-hood constipation: a pilot study. Nutr j 2007;6:17.
2. De Milliano I. et al. Is a multispecies probiotic mixture effective in constipa-tion during pregnancy? A pilot study Nutr J 2012, 11:80.
Reducing constipation
Clinical evidence
References
Ecologic® RELIEF has been tested in a clinical study, in collaboration with the Children’s Hospital of the Academic Medical Centre (AMC) of the Universi-ty of Amsterdam. Twenty children suf-fering from constipation used Ecolog-ic® RELIEF for four weeks (once daily). Results showed that Ecologic® RELIEF significantly increased amount of bowel movements per week, and decreased amount of abdominal pain and faecal incontinence (dirty underwear). No side effects were reported1 (see figure 1).
In addition, Ecologic® RELIEF has been tested in an open-label study again in collaboration with the AMC. During this study, 20 pregnant women suffer-ing from constipation as defined by the Rome III criteria consumed 4 grams (1x109 CFU/gram) Ecologic® RELIEF daily. Partic-ipants recorded daily amongst others, stool frequency and consistency, strain-ing, sensation of incomplete defecation, abdominal pain and adverse events in a standardized bowel diary. Intake of Ecologic® RELIEF resulted in a signifi-
cant increase in stool frequency; from 3.1 at baseline to 6.7 in week four (p<0.01). In addition, compared to baseline, a sig-nificant decrease was found in- straining (35%), - sensation of incomplete evacuation
(50%), - sensation of anorectal obstruction
(50%) - abdominal pain. No adverse effects were reported2.
Ecologic® RELIEF publications
0
10
20
B. Faecal incontinence (dirty underwear/week)
0
2
4
6
8
10
12
14
16
Faec
al in
cont
inen
ce/w
eek
A. Bowel movements (toilet visits/week)
Baseline 2 4 Baseline 2 4
Bow
el m
ovem
ents
/wee
k
C. Abdominal pain
Start
After 4 weeks 55%
40%
25%
20%
15%45%
Figure 1: Ecologic® RELIEF is able to significantly increase bowel movements (A), decrease faecal incontinence (B) and decrease abdominal pain (C).
P=0.10 P=0.007P=0.13 P=0.001
No Yes Sometimes
Weeks Weeks
The probiotic strains in Ecologic® RELIEF have been selected for their capacity to inhibit pathogen growth and improve motility and per-istalsis of the intestine. The strains have been screened in vitro for their capacity to:
• inhibit Clostridium difficile and Staphylococcus aureus• produce lactic acid.
Ecologic® RELIEF is a multispecies formulation consisting of 7 probiotic strains, 1 x 109 CFU/gram. The recommended dosage is 4 grams a day.
• B. bifidum W23• B. lactis W51• B. lactis W52• B. longum W108
Strain selection
• L. casei W79• L. plantarum W62• L. rhamnosus W71
Bacterial strains
1. Lamprecht M, et al. Probiotic supplementation affects markers of intestinal barrier, oxidation, and inflammation, before and after intense exercise; a randomized, double-blinded, placebo-controlled trial. J Int Soc Sports Nutr. 2012;9:45.
2. Strasser B, et al. Probiotic Supplements Beneficially Affect Tryptophan–Kynurenine Metabolism and Reduce the Incidence of Upper Respiratory Tract Infections in Trained Athletes: A Randomized, Double-Blinded, Placebo-Controlled Trial. Nutrients. 2016;8(11)
Reducing exercise-induced stress
Clinical evidence
References
Ecologic® PERFORMANCE has been test-ed in a randomized, double-blinded, placebo controlled trial at the Medical University of Graz, Austria. Twenty-three endurance sportsmen received Ecologic® PERFORMANCE or placebo for 14 weeks. Ecologic® PERFORMANCE significantly decreased stool zonulin levels (p=0,019), an important marker for a ‘leaky gut’. Moreover, a trend was shown towards a decrease in the chronic inflammatory
marker TNF-α (figure 1) and in the protein oxidation marker Carbonyl protein1.
In a randomized, double-blinded, pla-cebo controlled trial among 33 trained athletes at the Medical University of Inns-bruck, Ecologic® PERFORMANCE showed to significantly reduce the incidence of upper respiratory tract infections (URTIs). After 12 weeks of treatment, the proportion of subjects who experienced
one or more URTI symptoms during the study period was 2.2-fold higher in the pla-cebo group than in the probiotics group (p=0.016)2 (figure 2). Also, the athletes in the Ecologic® PERFORMANCE group could train 2.6 hours more per week compared to the control group (p<0.001)2. These re-sults show that Ecologic® PERFORMANCE could reduce the adverse effects of stress and offer support during heavy exercise training periods.
Ecologic® PERFORMANCE publications
Figure 2. Incidence of URTIs before and after 12 weeks of supplementation with Ecologic® PERFORMANCE. *Significant difference (p=0.016).
0
4
2
6
8
10
12
14
*
Ecologic® PERFORMANCE
Placebo
BaselineWeek 0 Week 12Week 14
Num
ber o
f ind
ivid
uals
with
URT
I
0
10
20
30
40
50
60
70
80
90
100
110
120
*
Figure 1: Effects of Ecologic® PERFORMANCE on TNF-α concentration. * After 14 weeks TNF-α was reduced by a trend in the Ecologic® PERFORMANCE
group compared to the placebo group (p=0.054).
Ecologic® PERFORMANCE pre stress test
Ecologic® PERFORMANCE post stress test
Placebo; pre stress test
Placebo; post stress test
pg/m
l
The bacterial strains in Ecologic® PERFORMANCE have been selected for their anti-inflammatory and oxidative properties and their abil-ity to improve the intestinal barrier function. The strains have been screened in vitro for their capacity to:• strengthen the epithelial barrier• reduce oxidative stress• induce the production of anti-inflammatory cytokines.
Ecologic® PERFORMANCE is a multispecies formulation consisting of 6 probiotic strains, 2,5 x 109 CFU/gram. The recommended dosage is 2 grams, twice daily.
• B. bifidum W23• B. lactis W51• E. faecium W54• L. acidophilus W22
Strain selection
• L. brevis W63• Lc. lactis W58
Bacterial strains
Preventing traveller’s diarrhoea
Clinical evidence
Winclove Travel has been tested in a pilot study with 200 travellers travelling to high-risk areas. The travellers took 5 grams of Winclove Travel once daily, starting a couple of days before their trip. All travellers filled out a diary during their trip, scoring their defecation pattern ac-cording to the Bristol stool scale. Results show that Winclove Travel is able to re-duce the risk of TD. Only 19% developed TD, which is normally 40%. Of the partici-pants 42% stated to have benefited from the formulation (figure 1).
The effect of individual, as well as com-binations of Winclove Travel strains on five intestinal pathogens (S. enteritidis, L. monocytogenes, E. coli O157:H7 (ETEC), C. sakazakii, C. jejuni) has been tested in vitro.1 All the strains showed antagonistic effects against the pathogens through different inhibitory mechanisms, includ-ing; antimicrobial activity, interference of adhesion of the pathogens to the intes-tinal wall, and growth competition/ex-clusion. Combinations of strains showed greater effect than single strains. As can
be seen in figure 2, single strains reduced the invasion ability of E.coli, however, strain combinations induced an even more remarkable effect. These results confirm the importance of multispecies formulations to potentiate beneficial ef-fects and indicate that supplementation with Winclove Travel could prevent TD.
The probiotic strains in Winclove Travel have been selected for their capacity to protect against pathogens known to cause traveller’s diarrhoea, such as; E.coli, Shigella and Salmonella, through:• producing antimicrobial agents• inhibiting pathogen adhesion• competing with pathogens for nutrients.
Winclove Travel is a multispecies formulation consisting of 8 pro-biotic strains, 1 x 109 CFU/gram. The recommended dosage is 5 grams a day. It is advised to start supplementation a couple of days before travel until the end of the journey.
• B. bifidum W23• B. lactis W51• L. acidophilus W37
Strain selection
• L. casei W56• L. plantarum W21• L. rhamnosus W71
• L. salivarius W24• Lc. lactis W58
Bacterial strains
42%
39%
19%
Stated to have benefited from Winclove Travel No effect Developed TD
Figure 1: Clinical evidence of 200 travellers taking Winclove Travel.
Figure 2: Invasion inhibition of ETEC by single and combinations of Winclove Travel strains measured in an exclusion and competition test. A decrease in CFUs (expressed on a log scale) indicates inhibition. * Significant effect (P <0.05).
1,0E+00
1,0E+01
1,0E+02
1,0E+03
1,0E+04
1,0E+05
* *** * *
Exclusion test Competition test
ETEC ETEC + W23 ETEC + W24 ETEC + W7 ETEC + ETEC + ETEC + ETEC + W23 + W23 + W24 W23 + W71 W24 + W71 W24 + W71
log
CFU
/ml
1. Campana R. et al. Strain-specific probiotic properties of lactic acid bacteria and their interference with humanintestinal pathogens invasion. Gut Pathog. 2017;9(12).
References Winclove Travel publication
Improving intestinal health in newborns
In vitro evidence
The most dominant genera in the healthy infant’s gut is Bifidobacterium. Therefore, Winclove Baby consists of four Bifido-bacterium species, of which research has shown to be present in the gut of infants3. These Bifidobacterium spe-cies can restore the balance of the new-born’s microbiota. Three strains of Winclove Baby have been added for their ability to inhibit growth of E. coli, a pathogen associated with in-fant colic. These strains have shown good capability to inhibit growth of E. coli (figure 1).
Maintenance of the intestinal barrier func-tion is critical for essential physiological processes. Three strains of Winclove Baby have been added for their ability to pro-tect the integrity of the intestinal lining. Their efficacy has been tested in a Trans Epithelial Electrical Resistance (TEER) mod-el. All strains were capable to strength-en the intestinal barrier function when a stressor was added. (figure 2).
Disruptions in the early microbiota can cause an imbalance in immune response regulating cells (Th1/Th2), which is one of the main mechanisms behind the devel-opment of allergies and asthma. All the strains in Winclove Baby are selected and tested to maintain a balanced immune system by inducing the production of IL-10; a cytokine with anti-inflammatory ef-fects. (figure 3).
0
5
10
15
20
0
5000
10000
15000
20000
25000
30000
40000
35000
0
10
20
30
40
50
60
70
90
80
100
0
5
10
15
20
0
5000
10000
15000
20000
25000
30000
40000
35000
0
10
20
30
40
50
60
70
90
80
100
0
5
10
15
20
0
5000
10000
15000
20000
25000
30000
40000
35000
0
10
20
30
40
50
60
70
90
80
100
Figure 1: Inhibition of E.coli by three strains in Winclove Baby. The larger the zone, the better the inhibition.
Figure 2: TEER data of three strains in Winclove Baby. The higher %TEER, the better the barrier function.
Figure 3: Production of the anti-inflammatory cytokine IL-10 after 24hr by the strains in Winclove Baby.
Inhi
bitio
n zo
ne (m
m)
% T
EER
IL-10
pro
duct
ion
afte
r 24h
r (pg
/ml)
Control Control ControlB. animalis W12
StressorB. lactis W51
Stressor+ B. animalis
W12
B. animalisW12
Stressor+ B. breve
W25
B. breveW25
Stressor+ B. lactis
W51
B. lactisW51
B. longumW108
B.longum W108
The probiotic strains in Winclove Baby are active on all three levels in the gut (external, barrier, systemic). The strains have been screened in vitro for their capacity to:• inhibit various pathogens such as; C. difficile and E. coli• improve the barrier function• influence the immune system.
Winclove Baby is a broad-spectrum, multi species formulation con-sisting of 4 probiotic strains, 1 x 109 CFU/gram. The recommended daily dosage is variable.• B. animalis W12• B. breve W25• B. lactis W51
Strain selection
• B. longum W108
Bacterial strains
Improving intestinal health in children
Clinical evidence
In a post-marketing study among thera-pists in the Netherlands it was investigat-ed for which indications Winclove Junior is prescribed and how its use is experi-enced (positive/negative). The results of this survey are shown in figure 1. As can be seen in the graph, Winclove Junior is prescribed for many health problems and shows the most satisfying effect (100%) for use during antibiotic use. Also for the other indications, high satisfaction scores (60%-80%) were obtained (data not pub-lished).
In addition, Winclove Junior has been studied in another post-marketing survey investigating the effect of Winclove Junior on childrens’ health. 80 children in the age of 0.5 – 6 years old used the probiotic for 6 weeks. A general health questionnaire was filled out by their healthcare profes-sional together with the parent(s). Results showed that Winclove Junior significantly increased health and improved appetite, see figure 2. The researchers reported no side-effects (data not published).
Figure 1: Results of a post-marketing survey with Winclove Junior.
Figure 2: Results of a post-marketing survey with Winclove Junior. * Significant effect.
0
20
40
60
80
100
4
5
6
7
8
9
10*
*
**
Posit
ive
resu
lts (%
)Po
sitiv
e re
sults
(%)
Antibiotics
Health as indicated
IBS
Mood
FoodIntolerance
Sleeprhythm
Constipation
Playfulness
FoodInfections
Appetite
RespiratoryTract
Infections
Crying andwining intensity
IBD
Stoolfrequence
Allergy
Stoolcomposition
Diarrhoea
Flatulance
Start 3 weeks 6 weeks
The probiotic strains in Winclove Junior are active on all three levels in the gut (external, barrier, systemic). The strains have been screened in vitro for their capacity to:• inhibit various pathogens such as; C. difficile, E. coli, Salmonella,
Shigella and P. agglomerans• improve the intestinal barrier function• stimulate a less allergic response of the immune system by; induc-
ing T-and B-cell proliferation, increasing IFN-y and IL-10 production and decreasing IL-5 and IgE production.
Winclove Junior is a broad-spectrum, multi species formulation con-sisting of 6 probiotic strains, 5 x 108 CFU/gram. The recommended daily dosage is variable.• B. lactis W51• B. lactis W52• L. acidophilus W55• L. casei W56• L. salivarius W57• Lc. lactis W58
Strain selection Bacterial strains
It has been shown in vitro that the strains in Winclove Adult are able to inhibit different pathogenic species such as; E. coli, E. faecalis and B. subti-lis. The strains have also shown to in-hibit Clostridium difficile, the pathogen which often causes diarrhea after the use of antibiotics. In addition, the com-plete formulation was tested on its abil-ity to inhibit E. coli and Salmonella and Shigella species (figure 1).
The effect of Winclove Adult on gut health and quality of life (QoL) was tested in an observational study. 40 adults with GI-complaints (but otherwise healthy) were supplemented for a 6-week pe-riod with Winclove Adult. The results show a significant reduction in the total GI-symptom score from 10 at baseline to 6 at the end of the intervention (p<0.05)1. The percentage of participants which were fully resolved of a particular symp-
tom significantly increased with 27.5% (p<0.02) for gastrointestinal pain, 25% (p<0.03) for epigastric fullness/bloating and 20% (p<0.02) for flatulence (see figure 2). There was an up-going trend in these scores, suggesting that further improve-ment could be expected on prolonged use of Winclove Adult. At the start of the study participants already reported a high quality of life; a slight improvement after 6 weeks of supplementation was seen.
Clinical and in vitro evidence
Improving intestinal health in adults
1. Grossenbacher F, Gashi A, Besseling-van der Vaart I. Use of the multispe-cies probiotic Winclove 500/Bactosan pro FOS leads to less gastrointes-tinal complaints in adults - an observational in vivo pilot study. Advances in Microbiology 2016; 6 (14): 975-985.
References Winclove Adult publication
Figure 1: Inhibition of E.coli, Salmonella and Shigella by Winclove Adult, tested in an in vitro well diffusion test. The larger the inhibition zone, the better the inhibition.
Figure 2: Percentage of participants that were asymptomatic for epigastric pain, epigastric fullness and flatu-lence after 6 weeks supplementation with Winclove Adult. * Significant increase (p<0.05).
0
2
4
6
8
10
12
14
16
18
0Baseline week 1 week 0 week 2 week 3 week 4 week 5 week 6
10
20
30
40
50
60
70
80
90
Inhi
bitio
n zo
ne (m
m)
Control E.coli Shigella sp. Salmonella sp.
Perc
enta
ge (%
) of p
artic
ipan
ts
that
are
asy
mpt
omat
ic
Epigastric pain Epigastric fullness Flatulence
*
The probiotic strains in Winclove Adult are active on all three levels in the gut (external, barrier, systemic). The strains have been screened in vitro for their capacity to:• inhibit various pathogens such as; C. difficile, E. coli, E. faecalis and
B. subtilus.• improve the barrier function• influence the immune system.
Winclove Adult is a broad-spectrum, multi species formulation con-sisting of 8 probiotic strains, 1 x 109 CFU/gram. The recommended daily dosage is variable.• B lactis W51• B. lactis W52• E. faecium W54• L. acidophilus W22
Strain selection
• L. paracasei W20• L. plantarum W21• L. salivarius W24• Lc. lactis W19
Bacterial strains
Improving intestinal health in elderly
In vitro evidence
Winclove Senior contains 10 bacterial strains. In addition, vitamin D3 has been added to the formulation. Vitamin D contributes, among others, to the maintenance of normal bones, teeth and muscle function. Vitamin D status is often impaired in elderly. Winclove Senior has been tested in vitro on:
• Inhibition of Clostridium difficile. Elderly are more susceptible to C. difficile infections. Three bacterial strains have been added to the formulation to inhibit growth of C. difficile. In vitro testing has shown excellent capability of these strains to inhibit C. difficile, see figure 1.
• Strengthening the barrier function. Ageing comes with an impaired intesti-nal barrier function. Three bacterial strains have been added to strengthen the intes-tinal barrier function. The results of in vitro testing with two strains in a Trans Epithe-lial Electrical Resistance (TEER) model are shown in figure 2. Both strains are very well capable of strengthening the intes-tinal barrier function. The third strain also performed well in a different model.
• Boosting the immune system. The immune system gradually decreases in older people. Three bacterial strains have been added to the formulation to boost the immune system. These strains have shown good induction of Th1 cells, which are involved in promoting immune responses and defence. (Results not shown).
Control stressor stressor + stressor + B. bifdum W23 B. animalis W53
Con
cent
ratio
n C
. diff
icile
(log
cfu
/ml)
Control L. paracasei L. salivarius L. rhamnosus W20 W24 W71
0,0
1,0
2,0
3,0
4,0
5,0
6,0
7,0
8,0
0
20
40
60
80
100
120
Figure 1: The inhibition of C. difficile and its toxins by three bacterial strains in Winclove Senior. The lower the concentration, the better the inhibition
% T
EER
0,0
1,0
2,0
3,0
4,0
5,0
6,0
7,0
8,0
0
20
40
60
80
100
120
Figure 2: The capacity of two bacterial strains in Winclove Senior to strengthen the intestinal barrier function. The higher %TEER, the better the barrier function.
C. difficile after 48hr Toxins after 48hr
The probiotic strains in Winclove Senior are active on all three levels in the gut (external, barrier, systemic). The strains have been screened in vitro for their capacity to:
• inhibit various pathogens such as; E. coli, Salmonella, Shigella and P. agglomerans
• improve the intestinal barrier function• influence the immune system.
Winclove Senior is a broad-spectrum, multi species formulation con-sisting of 10 probiotic strains, 1 x 109 CFU/gram. The recommended daily dosage is variable.• B. animalis W53• B. bifidum W23• B. lactis W51• B. lactis W52• L. acidophilus W22• L. paracasei W20
Strain selection
• L. plantarum W1• L. rhamnosus W71• L. salivarius W24• Lc. lactis W19and vitamin D3
Bacterial strains
The information in this brochure is intended for business professionals only and should not be given to consumers.
Interested? Don’t hesistate to contact us,we look forward to hearing from you!
Winclove ProbioticsHulstweg 111032 LB Amsterdam, The Netherlands+31 (0)20-435 02 [email protected]
P R O B I O T I C S
All probiotic strains have the Qualified Presumption of Safety Status (QPS). Winclove is a NSF International Certified GMP facility for manufacturing dietary supplements. Winclove’s food safety management system is ISO 22000:2005 certified for the development and production of prebiotics and probiotics. Both our formulations and manufacturing processes are controlled by certified, external laboratories.